FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to an antibody to FXI/FXIa or its antigen-binding fragment. In addition, the present invention also relates to a polynucleotide coding said antibody or an antigen-binding fragment thereof, an expression vector containing said polynucleotide, a host cell, a method for producing such an antibody, as well as a pharmaceutical composition for treating a disease or disorder associated with thrombosis or thromboembolism, use of said antibody, polynucleotide and vector for preparing a drug or pharmaceutical composition and a method of treating.
EFFECT: present invention provides antibodies to FXI/FXIa with low immunogenicity, which effectively inhibit thrombosis without increasing risk of bleeding.
23 cl, 14 dwg, 7 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
| ANTIBODIES TO FACTOR XI | 2017 |
|
RU2800719C2 |
| NEW ANTIBODIES AGAINST XI FACTOR AND THEIR APPLICATIONS | 2017 |
|
RU2758160C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
| ST2 ANTIGEN BINDING PROTEIN | 2021 |
|
RU2841164C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND USE THEREOF | 2020 |
|
RU2822550C2 |
